Publications by authors named "M Fiala"
Article Synopsis
- Multiple Myeloma (MM) is an incurable cancer affecting plasma cells, with over 35,000 new cases diagnosed each year in the U.S., leading to frequent relapses and limited treatment options.
- Researchers used transcriptome sequencing to compare newly diagnosed MM patients with short progression-free survival (PFS) to those with longer PFS, identifying 157 lncRNAs associated with poor outcomes, particularly focusing on one specific lncRNA.
- The study found that the overexpression of this lncRNA enhances cell viability and decreases apoptosis, while its knockdown has the opposite effect, and targeted therapies using antisense oligonucleotides showed potential in reducing cell viability and promoting apoptosis in MM cells.
Introduction: Patients with triple-class refractory (TCR) multiple myeloma (MM) often need cytoreductive chemotherapy for rapid disease control. Bendamustine is an outpatient-administered, bifunctional alkylator and isatuximab is an anti-CD38 monoclonal antibody with unique cytotoxicity characteristics. We hypothesized that isatuximab-bendamustine-prednisone would be well-tolerated regimen in TCR MM, and conducted single-center, phase Ib, investigator-initiated study.
View Article and Find Full Text PDFMultiple myeloma (MM) is the cancer of plasma cells within the bone marrow and remains incurable. Tumor-associated macrophages (TAMs) within the tumor microenvironment often display a pro-tumor phenotype and correlate with tumor proliferation, survival, and therapy resistance. IL-10 is a key immunosuppressive cytokine that leads to recruitment and development of TAMs.
View Article and Find Full Text PDFTreatment Access among Younger Medicaid Beneficiaries with Multiple Myeloma.
Clin Lymphoma Myeloma Leuk
August 2024
Purpose: Continuous Medicaid coverage prior to a cancer diagnosis has been associated with earlier detection and better outcomes, for patients with solid tumors. In this study, we aimed to determine if this was observed among patients with multiple myeloma, a hematologic cancer where there are no routine screening tests and most are diagnosed through acute medical events.
Materials And Methods: This is an analysis of the Merative MarketScan Multistate Medicaid Database, a claims-based dataset.